Anti-CD44 Variant 10 Monoclonal Antibody Exerts Antitumor Activity in Mouse Xenograft Models of Oral Squamous Cell Carcinomas.
Animals
Hyaluronan Receptors
/ metabolism
Mice
Mouth Neoplasms
/ drug therapy
Humans
Antibodies, Monoclonal
/ pharmacology
Cell Line, Tumor
Xenograft Model Antitumor Assays
CHO Cells
Carcinoma, Squamous Cell
/ drug therapy
Cricetulus
Antineoplastic Agents, Immunological
/ pharmacology
Antibody-Dependent Cell Cytotoxicity
/ drug effects
Cell Proliferation
/ drug effects
Mice, Inbred BALB C
ADCC
CD44v10
CDC
monoclonal antibody therapy
oral cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
02
08
2024
revised:
20
08
2024
accepted:
22
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
14
9
2024
Statut:
epublish
Résumé
CD44 regulates cell adhesion, proliferation, survival, and stemness and has been considered a tumor therapy target. CD44 possesses the shortest CD44 standard (CD44s) and a variety of CD44 variant (CD44v) isoforms. Since the expression of CD44v is restricted in epithelial cells and carcinomas compared to CD44s, CD44v has been considered a promising target for monoclonal antibody (mAb) therapy. We previously developed an anti-CD44v10 mAb, C
Identifiants
pubmed: 39273139
pii: ijms25179190
doi: 10.3390/ijms25179190
pii:
doi:
Substances chimiques
Hyaluronan Receptors
0
Antibodies, Monoclonal
0
Antineoplastic Agents, Immunological
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 24am0521010 (to Y.Kato), JP23ama121008 (to Y.Kato), JP23am0401013 (to Y.Kato), JP23bm1123027 (to Y.Kato), and JP23ck0106730 (to Y.Kato)
Organisme : Japan Society for the Promotion of Science
ID : 22K06995 (to H.S.), 21K20789 (to T.T.), 21K07168 (to M.K.K.), and 22K07224 (to Y.Kato)